Calmark strengthens logistics and order processing in preparation of global launch
Calmark Sweden AB has hired Liana Rikberg for the role as Supply Chain Coordinator in order to strengthen its team for the global launch. Liana will take up position on January 10, 2022.
Liana Rikberg has more than ten years of experience in logistics solutions from her employment at Federal Express (FedEx) where her work involved imports, exports, order management and invoicing. Liana Rikberg has also worked as Supply Chain Administrator at Hamamatsu. Liana is currently a consultant for Academic Work and has been working for Calmark in this role since October 1.
“I am so happy to be part of Calmark and get the opportunity to work with such a lovely and dedicated team to move the business forward,” says Liana Rikberg. “It is very exciting to join the company at such an early stage and be able to witness the growth and development of Calmark.”
"I am delighted that Liana wanted to start working for Calmark as an employee," says Anna Söderlund, CEO. “In view of the forthcoming global launch, we need to ensure our capacity at all stages. Liana will be essential for ensuring the efficiency of order and logistic flows, and I wish her a warm welcome on board!”
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se
www.calmark.se
Calmark Sweden AB is a medical technology company that develops and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark sells a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.
